基于中国人群的糖尿病治疗药物经济学评价文献的系统评估和质量评价

Systematic assessment and quality evaluation of literatures on economic evaluation of diabetes drugs in Chinese population

目的系统回顾基于中国人群糖尿病治疗药物的经济学研究,为促进我国糖尿病领域药物经济学研究的开展和研究质量的提升提供参考。方法检索PubMed、Embase、中国生物医学文献服务系统、中国知网、万方数据和维普网等数据库,收集基于中国人群的糖尿病治疗药物经济学评价文献,对文献的发表情况、研究内容、研究设计等进行分析,并使用“卫生经济学评价报告标准共识2013(CHEERS 2013)清单”对文献报告质量进行评价。结果共纳入相关文献380篇,包括中文文献348篇、英文文献32篇。首篇基于中国人群的糖尿病治疗药物的经济学评价文献于2001年发表;评价最多的药物为二甲双胍;大部分研究由医疗机构开展(79.2%),多为短期经济性评价(73.9%)、方法主要为成本-效果分析(61.8%),且大部分未报告明确的研究角度(82.6%)。经CHEERS 2013清单评价,纳入文献的平均得分为10.57分,85.8%的文献报告质量不合格。中文文献的平均得分为10.05分,英文文献的平均得分为16.23分,英文文献的报告质量明显优于中文文献(P<0.001)。结论现有的基于中国人群的糖尿病治疗药物经济学评价文献研究质量较低,存在研究角度缺失、研究机构/方法单一、报告不规范等问题。建议医疗机构、高校/研究院、企业和政府部门等机构加强合作,提高研究水平,并关注更多、更新的临床有效治疗方案,促进研究结果的证据转化。

OBJECTIVE To review economic studies of diabetes drugs in Chinese population systematically,and to provide reference for promoting the development of pharmacoeconomics research in the field of diabetes and improving the research quality.METHODS Retrieving from PubMed,Embase,SinoMed,CNKI,Wanfang data,VIP and other databases,the literatures on economic evaluation of diabetes drugs in Chinese population were collected;analysis was carried out on the publication,research content,study design of the literatures.The Consolidated Health Economic Evaluation Reporting Standards 2013(CHEERS 2013)checklist was used for quality evaluation.RESULTS A total of 380 literatures were included,involving 348 Chinese literatures and32 English literatures.The first paper of diabetes drugs in Chinese population was published in 2001.The most evaluated drug was metformin.Most of the studies(79.2%)were conducted by medical institutions,73.9%of the studies were short-term economic evaluation,and the methods were mainly cost-effectiveness analysis(61.8%),and most of the studies did not reported clear research perspectives(82.6%).Evaluated by CHEERS 2013,the average score of included literatures was only 10.57,and 85.8%of the literatures was of unqualified quality.The average score of Chinese literatures was 10.05,that of English literatures was16.23,and the reporting quality of English literatures was significantly better than that of Chinese literatures(P<0.001).CONCLUSIONS The existing literatures on the economic evaluation of diabetes drugs in Chinese population is of low quality.There are problems such as lack of research perspectives,single research institution/method,and non-standard reporting.It is recommended that medical institutions,universities/research institutions,enterprises,government and other institutions should strengthen cooperation,improve their research level,pay attention to more and newer clinically effective treatment regimens,and promote the transformation of research results into decision-making evidence.